TP53 and osteosarcoma: To further examine the effect of Vitex on the viability of p53 mutant-type osteosarcoma MG63 cells and p53 wild-type osteosarcoma SJSA1 cells treated with an anti-osteosarcoma drug (Methotrexate), Vitex was administered for 24 h, and the cell viability was analysed using an MTT assay.